Citadel Advisors’s ProShares Ultra CRCL CRCA Stock Holding History

Citadel Advisors’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$601K	Buy	46,920 +27,440	+141%	+$1.06M	﹤0.01%	9420
2026 Q1	$804K	Buy	19,480 +13,180	+209%	+$547K	﹤0.01%	8171
2025 Q4	$255K	Buy	6,300 +2,820	+81%	+$242K	﹤0.01%	10510
2025 Q3	$509K	Buy	+3,480	New	+$560K	﹤0.01%	9089

Other funds holding CRCA

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Citadel Advisors's CRCA Position: Q2 2026 in Review

Citadel Advisors sold out of ProShares Ultra CRCL (CRCA) in Q2 2026, closing a stake of 47,007 shares — an estimated $1.81M sold.

Citadel Advisors first reported a position in CRCA in Q4 2025 and held it in 2 quarters. The position peaked at $1.94M in Q1 2026. 7 funds tracked by Wall St. Rank hold CRCA as of Q2 2026.

Citadel Advisors reported no remaining ProShares Ultra CRCL position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 47,007 ProShares Ultra CRCL shares in Q2 2026, an estimated $1.81M.
Citadel Advisors first reported a position in ProShares Ultra CRCL in Q4 2025 and held it in 2 quarters.
Citadel Advisors's ProShares Ultra CRCL position peaked at $1.94M in Q1 2026.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.